This site is intended for healthcare professionals
Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.
Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.
NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS
Medac has launched Metoject PEN (methotrexate) a single-use...
BMS has launched a prefilled syringe presentation of...
NICE has overturned its original decision to reject...
The most up-to-date drug information at your fingertips.
Product overviews prepared by the MIMS team, in a handy slide format.
Slides are initiated, funded & reviewed by the companies specified.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
Drugs
Conditions
Travel
Articles
